It is gearing up to be a big week for Amarin (AMRN), as it awaits the opening of the appeal case for its high triglyceride treatment, Vascepa.To recap, in March, Amarin lost a patent court case against generic drug makers, Hikma Pharmaceuticals and Dr. Reddy’s, which sought to sell their own versions of Vascepa. Amarin immediately filed an appeal, and an oral hearing will commence on Wednesday, September 2.Ahead of the court date, Stifel analyst Derek Archila consulted with two IP specialists on the matter, and both have indicated Amarin has a 55% chance of succeeding in its appeal. However, …read more
Source:: Yahoo Finance
